Clinical trial
Phase 2 Study Of Neoadjuvant Iressa Treatment In Stage 1 NSCLC
NCT00188617 · University Health Network, Toronto, Other · Completed
Key facts
| NCT number | NCT00188617 |
|---|---|
| Title | Phase 2 Study Of Neoadjuvant Iressa Treatment In Stage 1 NSCLC |
| Official title | Phase II Study Of Single Agent Gefitinib (Iressa) In Patients With Clinical Stage I Non-Small Cell Lung Cancer (NSCLC) Proceeding To Mediastinoscopy And Surgery |
| Lead sponsor | University Health Network, Toronto, Other |
| Collaborators | AstraZeneca Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | LUNG CANCER |
| Intervention type | Drug |
| Interventions | GEFITINIB |
| Enrollment | 35 |
| Start date | Jan 1, 2005 |
| Primary completion | Jun 1, 2007 |
| Completion | Nov 1, 2009 |
| First posted | Sep 16, 2005 |
| Last update posted | Mar 14, 2017 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: